Oxidative stress

Mental Performance Is the #1 Factor for Healthy Aging, According to Life Extension Survey

Retrieved on: 
Tuesday, April 9, 2024
Ageing, Brain, Dementia, Longevity, Nutrient, Resveratrol, New product development, Taurine, Memory, Life, Spermidine, MD, MBA, Lithium, Cognition, Life extension, Oxidative stress, Dietary supplement

So what’s more important when it comes to healthy aging: brain or brawn?

Key Points: 
  • So what’s more important when it comes to healthy aging: brain or brawn?
  • †February 2024 survey of Life Extension customers.
  • According to Michael A. Smith, MD , Life Extension’s Director of Education, aging healthily goes beyond flexing strong muscles; it also depends on heart health and, yes, cognition.
  • “Physical health is a no-brainer when it comes to healthy aging, but many don’t realize that maintaining cognitive health and performance, including a healthy mood, is also crucial,” Dr. Smith said.

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24

Retrieved on: 
Monday, April 8, 2024
Vitamin E, Plasma, Rosuvastatin, Inflammation, Nitric oxide, Protein, EPA, Angiotensin, Endothelial dysfunction, Oxidative stress, Dietary supplement

These findings indicate that the net benefits of a high intensity statin and EPA, compared to statin alone, on expression of detoxification proteins during inflammation may contribute to reduced atherothrombotic risk in outcome trials.

Key Points: 
  • These findings indicate that the net benefits of a high intensity statin and EPA, compared to statin alone, on expression of detoxification proteins during inflammation may contribute to reduced atherothrombotic risk in outcome trials.
  • The beneficial effects of a high intensity statin and EPA on endothelial dysfunction may contribute to reduced atherothrombotic risk in outcome trials.
  • Elevated Lp(a) levels are an independent and causal risk factor for cardiovascular (CV) disease with limited treatments available.
  • The potent antioxidant actions of EPA may contribute to reduced CV events in REDUCE-IT, including among those subjects with elevated Lp(a).

Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy

Retrieved on: 
Friday, April 5, 2024
Retina, Disease, Inflammation, Patient, Data, Cohort, Șaeș, Life, Clinical trial, Armada, MPH, Injection, Safety, DSMB, FACS, Vaccine, Lipid metabolism, Geographic atrophy, Oxidative stress, Pharmaceutical industry

Three subjects with geographic atrophy (GA) were dosed in the Phase 1/2 clinical trial to date.

Key Points: 
  • Three subjects with geographic atrophy (GA) were dosed in the Phase 1/2 clinical trial to date.
  • An additional three subjects will be dosed with the medium dose (Cohort 2) and three patients with the high dose (Cohort 3) of OCU410 in the dose-escalation phase.
  • “The DSMB has recommended moving forward to medium dose for dosing subjects with GA,” said Dr. Peter Chang, MD, FACS, DSMB Chair for the OCU410 clinical trial.
  • Phase 1 is a multicenter, open-label, dose-ranging study consisting of three dose levels [low dose (2.5×1010 vg/mL), medium dose (5×1010 vg/mL), and high dose (1.5 ×1011 vg/mL)].

Ocugen Provides Business Update with Certain Financials for the Year Ending 2023

Retrieved on: 
Tuesday, April 2, 2024
Stargardt disease, Disease, Safety, Webcast, Inflammation, Patient, CGMP, Data, Inhalation, Cohort, RP, Life, Bank statement, Investment, Clinical trial, NIAID, Injection, AMD, Vaccine, Nextgen, Geographic atrophy, RHO, FDA, Lipid metabolism, Government, Oxidative stress, Pharmaceutical industry

Completed Cohort 1 dosing for OCU410 and OCU410ST gene therapy clinical studies for geographic atrophy (GA) and Stargardt disease, respectively

Key Points: 
  • Completed Cohort 1 dosing for OCU410 and OCU410ST gene therapy clinical studies for geographic atrophy (GA) and Stargardt disease, respectively
    MALVERN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today provided a general business update with certain financials for the year ending 2023.
  • During the fourth quarter of 2023, the Company announced its mucosal vaccine candidate, OCU500, was chosen for the multi-billion-dollar NIAID Project NextGen initiative.
  • The first patient was dosed in the Phase 1/2 trials to assess the safety and efficacy of OCU410ST for Stargardt disease in November 2023.
  • Ocugen’s cash, cash equivalents, and investments totaled $39.5 million as of December 31, 2023, compared to $90.9 million as of December 31, 2022.

Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation Challenge

Retrieved on: 
Tuesday, March 12, 2024
Dermatology, Atopic dermatitis, Inflammation, JNJ, Research, American Academy, Cancer, FABP5, Skin, FABP, Pain, Epidermis, Oxidative stress, Pharmaceutical industry

SOLANA BEACH, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced its selection as a finalist in Johnson & Johnson’s (“J&J’s”; NYSE: JNJ) Innovation Challenge .

Key Points: 
  • SOLANA BEACH, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced its selection as a finalist in Johnson & Johnson’s (“J&J’s”; NYSE: JNJ) Innovation Challenge .
  • Artelo was awarded the opportunity to present preclinical dermatology research on ART26.12 in San Diego, California, on March 11, 2024, concurrent with the American Academy of Dermatology Annual Meeting.
  • "We are pleased to have been selected to present our ART26.12 program to the J&J immuno-dermatology leadership team," said Dr. Andrew Yates, Chief Scientific Officer of Artelo.
  • “Our drug discovery program is investigating several oral, small molecule, FABP5 inhibitors,” said Professor Saoirse O'Sullivan, Vice President Translational Science of Artelo.

Arctic Therapeutics and Nacuity Pharmaceuticals Announce European Medicines Agency Approval to Initiate First Clinical Trial of AT-001 (NPI-001) for the Treatment of HCCAA

Retrieved on: 
Tuesday, March 12, 2024
Retinitis pigmentosa, Disease, Partnership, Tablet, SVP, Stroke, Deficit spending, EMA, Cystinosis, GMP, European Medicines Agency, Clinical trial, Intraparenchymal hemorrhage, NACA, Safety, CSO, Cataract, Usher syndrome, Dementia, Oxidative stress, Amyloid, Service provider, Pharmaceutical industry

Current treatment options are severely limited, focusing primarily on symptom management rather than addressing the underlying cause of the disease.

Key Points: 
  • Current treatment options are severely limited, focusing primarily on symptom management rather than addressing the underlying cause of the disease.
  • “EMA's approval paves the way for a comprehensive investigation into the safety and efficacy of a novel therapeutic approach designed to halt or reverse the progression of HCCAA.
  • Nacuity is also currently evaluating NPI-001 in Phase 1/2 clinical trials in Australia for retinitis pigmentosa associated with Usher syndrome and cystinosis.
  • “Our proprietary NPI-001 has potential to address the myriad diseases and conditions where oxidative stress plays a role.

Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Retrieved on: 
Monday, March 18, 2024
Pharmaceutical, Health, Neurology, Clinical Trials, Depression, Metabolism, Brain, NCE, Acute stress disorder, Concussion, Veterans' affairs, Executive, Common, Inflammation, Patient, United States Congress, TBI, Foundation (nonprofit), Anxiety, CTE, University, Military personnel, Oxidative stress, Human, GMP, Nasal cavity, Traumatic brain injury, DSM-IV codes, Phase, Traffic, Swelling, FDA, Animal, Pentagon, Chronic traumatic encephalopathy, Phase II, Marcus Foundation, Medical device

Oragenics’ lead drug candidate, ONP-002 is combined with its intranasal device intended for the treatment of mild Traumatic Brain Injury (TBI), aka concussion.

Key Points: 
  • Oragenics’ lead drug candidate, ONP-002 is combined with its intranasal device intended for the treatment of mild Traumatic Brain Injury (TBI), aka concussion.
  • Dr. Kelly was also National Director of the Avalon Action Alliance TBI Programs for which the MIBH serves as the clinical coordinating center.
  • “I am excited to join Oragenics as its Chief Medical Officer at such an important and pivotal time in the drug development process.
  • Dr. Kelly has interacted with the FDA and clinical trials for brain injury throughout his esteemed career.

Coya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference

Retrieved on: 
Tuesday, March 12, 2024
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, Diagnosis, Pharmacology, LD, Conference, Survival, Serum, Coya, Disease, ALS, Associate, Patient, Biomarker, COYA, ROS, Death, Reactive oxygen species, Society, Therapy, Patent, FDA, Oxidative stress

The data presented highlights the strong predictive value of levels of an oxidative stress biomarker (4-HNE) with the rate of disease progression and survival in 50 ALS patients from a longitudinal patient registry cohort.

Key Points: 
  • The data presented highlights the strong predictive value of levels of an oxidative stress biomarker (4-HNE) with the rate of disease progression and survival in 50 ALS patients from a longitudinal patient registry cohort.
  • In a proof-of-concept study in patients with ALS, the combination of low dose interleukin-2 (LD IL-2) and CTLA-4 Ig appeared to lower 4-HNE and other proinflammatory biomarker levels.
  • Furthermore, Coya has filed patent applications relating to the use of the biomarker in ALS.
  • Data was collected from a previously established biobank at Houston Methodist to monitor and track ALS patient outcomes with biomarkers.

Journal of Pharmaceutical Analysis (JPA) Studies Find Promising Drug Candidates

Retrieved on: 
Friday, March 29, 2024
Hydralazine, Issue 1, DHT, Pigment, UBA52, Neuroregeneration, Prevalence, Apoptosis, PNI, Serum, Homeostasis, Patient, Ferroptosis, JPA, Neuron, HYD, Metformin, Type, Nerve, BPH, Hypopigmentation, EB, Depigmentation, Met, Oxidative stress, Iron, Pharmaceutical industry

XI'AN, China, March 29, 2024 /PRNewswire/ -- Understanding the underlying mechanisms of normal and pathological cellular processes is essential for developing new drugs. Fortunately, modern techniques and experimental methods have greatly accelerated progress. The latest issue of JPA features three articles in which candidate compounds for treating complex disorders were successfully identified, alongside their detailed mechanisms of action.

Key Points: 
  • The first study investigated the use of metformin (Met), a drug used to manage type II diabetes, for treating benign prostate hyperplasia (BPH).
  • The article was published in Volume 14, Issue 1 of the journal in January 2024 .
  • Using the Drug Signatures Database, they identified hydralazine (HYD), a potent arterial vasodilator, as a potential UBA52 disruptor.
  • Further studies will hopefully clarify the intricate connections among cellular processes, diseases, and potential drugs, paving the way for precise and efficient therapies.

MOJO Health Launches Revolutionary EMF Shielding Tranquility Blanket

Retrieved on: 
Monday, March 25, 2024
Immune system, Oxidative stress, Wi-Fi, EMF, Health, Tablet, Tranquillity, Wrist, Love, Cancer, Mobile phone

ATLANTA, March 25, 2024 /PRNewswire-PRWeb/ -- In efforts to further its mission to make holistic healthcare accessible to all and to evolve the cancer healing process to include the best of both conventional and traditional healing methodologies, MOJO Health is excited to announce the launch of its revolutionary EMF Shielding Tranquility Blanket.

Key Points: 
  • ATLANTA, March 25, 2024 /PRNewswire-PRWeb/ -- In efforts to further its mission to make holistic healthcare accessible to all and to evolve the cancer healing process to include the best of both conventional and traditional healing methodologies, MOJO Health is excited to announce the launch of its revolutionary EMF Shielding Tranquility Blanket.
  • It's critical to use every resource, like our Tranquility Blanket, to protect the body from potential negative EMF impacts.
  • "It's critical to use every resource, like our Tranquility Blanket, to protect the body from potential negative EMF impacts.
  • The EMF Shielding Tranquility Blanket is available now on Mojohealth.org for $198.00 for the first 150 blankets sold!